Bone Foam, Inc. Announces Buzz Hannahan as Chief Executive Officer

February 1  

Medical Alley, MN – February 1, 2022

Bone Foam, Inc. today announced that its Board of Directors appointed Buzz Hannahan as its next Chief Executive Officer, effective February 1, 2022. The company’s executive team and Board of Directors formed the search committee, culminating a recruitment process that spanned the majority of 2021. Hannahan will also join the company’s Board of Directors upon assuming his new role, while Chad Robran will transition from President and CEO and continue service on the company’s Board of Directors. With nearly two decades of medical device experience at Becton Dickinson and then Zimmer Inc., following a 9-year professional baseball career with the Philadelphia Phillies organization, Hannahan steps into an opportunity to leverage his executive sales and marketing expertise on behalf of a company that has grown nearly fourfold in as many years.

“This leadership transition occurs during a period of significant positive momentum across the organization,” said Peter Cole, Executive Vice President of Bone Foam, Inc. “This month marks the three year anniversary of our expansion strategy – focused on product innovation and distribution – which set the foundation for a credible model to reach aggressive growth targets on a compounding basis. Buzz’s relentless focus on the customer as a top sales and business development executive, as well as his strong track record of grit dating back to his playing days, are just a few of the transformational elements of his candidacy that position him well to successfully lead a company with a broad but underpenetrated footprint. Our Board of Directors is confident Buzz is the right leader to guide Bone Foam into its next era of growth as we continue to change the patient positioning paradigm in favor of value-based standards,” Cole continued.

Bone Foam has built a respected brand with inventory in over 7,000 accounts worldwide, a foundation which spans multiple specialties and subspecialties in 2022. “I am deeply honored and humbled to have the opportunity to lead Bone Foam into the next phase of our important journey to be the unequivocal leader in patient positioning,” said Hannahan. “Our dedication to creating clinical distinction has driven significant growth over the course of our history. Together with the Bone Foam team, we will work to build upon our strong foundation and continue to advance better methods for surgical procedures that have languished in the status quo ever since I first stepped foot in the operating room in 2007. I am highly confident about our company’s future and look forward to further accelerating the value we bring to our patients and providers. I would like to thank the Board of Directors for this opportunity. I would also like to thank Chad for his leadership over two decades. I can’t wait to meet the team”

Under Robran’s leadership, Bone Foam developed from a popular line of products into a company with robust infrastructure and capabilities. It brought to market its highest-selling product by volume in the Zero Degree Knee – used by well over 75,000 patients worldwide recovering from knee surgery – which spurred the onset of MyComfortMD, Bone Foam’s direct to consumer division. It executed its first corporate acquisition in the Troop Elevation Pillow product line, which further diversified Bone Foam’s portfolio into the Anesthesiology and disposables space. It not only survived but grew double in size through the pandemic. In doing so, Bone Foam largely pioneered the patient positioning market. Robran drew an interesting parallel between his first and latest career endeavor: “When I began my career at Pfizer, the FDA had just approved Viagra, the solution for a problem that people did not know existed. In other words, the treatment for ED predated the diagnosis. Similarly, Bone Foam provided a solution for a problem that people did not know existed. People did not pay attention to the waste of time and costs associated with prepping patients for surgery because there was no solution for it. Now, people are taking notice.”

“No discussion of Chad’s leadership would be complete without recognizing his unfaltering commitment to the end user and to the team,” said Cole. “As a company, we can speak with confidence of the proud legacy of enhancing care for patients dating back to 2001, when the original Trauma Kit of 15 soft-foam positioners provided an exciting portfolio and genre.” Added Mark Christoperson, Bone Foam Board member and CEO of Cryosa, “Having scaled significantly in a short timespan, Bone Foam finds itself at a critical crossroads. We are excited about how Buzz’s commercial acumen will translate into more and more providers and institutions buying in to ‘The Bone Foam Way’ of patient positioning.”

Others throughout industry are equally bullish about the Hannahan hire. “I have known Buzz for more than 10 years and have continually been impressed with his leadership, integrity, versatility, and creativity. During this time, Buzz and I have been in many joint business opportunities and I have observed him build key relationships from front line users to C-Suite executives, create strategies and develop business needs,” said Russ Funk, CEO of Banner Pharmacy Services. “Additionally, I have watched him lead the west region as he has continued to develop business strategies and individuals providing them the ability to accomplish more than they ever believed they could. I believe that Buzz will do an amazing job as CEO and look forward to watching him grow the Bone Foam market.”

After his professional baseball career with the Philadelphia Phillies organization (1998-2006), Hannahan broke into healthcare as an Orthopaedic Trauma medical device sales representative, learning the ropes at then Zimmer Inc. where he achieved top sales status, moving up the ranks to Regional Sales Director (2007-2013). Hannahan then moved healthcare domains into Medication Management Solutions with Becton Dickenson in 2013, and after executing on over $28 Million in revenue by 2015 and ranking #1 nationally in competitive sales, was promoted to Care Continuum, West Director of Sales where he managed the Pyxis Technologies Portfolio of $70 Million and performed perennially in the top decile nationally, driving revenue and margin for Medication Management Capital, EMR Integration, and services. Hannahan is best known for his top team engagement, visionary mindset, patient-centered approach, intelligent strategy, and highly competitive spirit.

About Bone Foam

Bone Foam, Inc. is a leading medical device company specializing in innovating pre-contoured positioning solutions around a growing list of surgical procedures and rehabilitation indications. Four pillars define Bone Foam’s mission: To be the unequivocal leader in perioperative patient positioning by innovating the highest quality solutions that optimize safety, efficiency, cost, and clinical experience. Its portfolio includes cutting-edge solutions for Orthopaedic Trauma, Spine, Arthroplasty, Hand, Shoulder & Elbow, as well as Anesthesiology and Pulmonology, with penetration in over 7,000 hospitals and surgery centers globally.

Success message!
Warning message!
Error message!